Literature DB >> 22868502

Anthracycline-induced cardiotoxicity: cardiac monitoring by continuous wave-Doppler ultrasound cardiac output monitoring and correlation to echocardiography.

Sandra Geiger1, Hans Joachim Stemmler, Patricia Suhl, Petra Stieber, Veronika Lange, Dorothee Baur, Andreas Hausmann, Johanna Tischer, Sophia Horster.   

Abstract

BACKGROUND: Anthracyclines are agents with a wellknown cardiotoxicity. The study sought to evaluate the hemodynamic response to an anthracycline using realtime continuous-wave (CW)-Doppler ultrasound cardiac output monitoring (USCOM) and echocardiography in combination with serum biomarkers.
METHODS: 50 patients (26 male, 24 female, median age 59 years) suffering from various types of cancer received an anthracycline-based regimen. Patients' responses were measured at different time points (T0 prior to infusion, T1 6 h post infusion, T2 after 1 day, T3 after 7 days, and T4 after 3 months) with CW-Doppler ultrasound (T0-T4) and echocardiography (T1, T4) for hemodynamic parameters such as stroke volume (SV; SVUSCOM ml) and ejection fraction (EF; EFechocardiography%) and with NT-pro-BNP and hs-Troponin T (T0-T4).
RESULTS: During the 3-month observation period, the relative decrease in the EF determined by echocardiography was -2.1% (▵T0-T4, T0 71 ± 7.8%, T4 69.5 ± 7%, p = 0.04), whereas the decrease in SV observed using CW-Doppler was -6.5% (▵T0-T4, T0 54 ± 19.2 ml, T4 50.5 ± 20.6 ml, p = 0.14). The kinetics for serum biomarkers were inversely correlated.
CONCLUSIONS: Combining real-time CW-Doppler USCOM and serum biomarkers is feasible for monitoring the immediate and chronic hemodynamic changes during an anthracycline-based regimen; the results obtained were comparable to those from echocardiography.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22868502     DOI: 10.1159/000338335

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  6 in total

Review 1.  Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts.

Authors:  Gina Biasillo; Carlo M Cipolla; Daniela Cardinale
Journal:  Curr Oncol Rep       Date:  2017-08       Impact factor: 5.075

Review 2.  Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.

Authors:  Eric S Christenson; Theodore James; Vineet Agrawal; Ben H Park
Journal:  Clin Biochem       Date:  2014-11-07       Impact factor: 3.281

3.  Cardiotoxicity After Anthracycline Treatment in Survivors of Adult Cancers: Monitoring by USCOM, Echocardiography and Serum Biomarkers.

Authors:  Alessandro Pastore; Sandra Geiger; Dorothee Baur; Andreas Hausmann; Johanna Tischer; Sophia Horster; Hans Joachim Stemmler
Journal:  World J Oncol       Date:  2013-03-06

4.  Non-invasive assessment of cardiac hemodynamics in patients with advanced cancer and with chronic heart failure: a pilot feasibility study.

Authors:  Stephan von Haehling; Mitja Lainscak; Thomas Kung; Larissa Cramer; Susann Fülster; Uwe Pelzer; Bert Hildebrandt; Anja Sandek; Joerg C Schefold; Mathias Rauchhaus; Wolfram Doehner; Stefan D Anker
Journal:  Arch Med Sci       Date:  2013-04-22       Impact factor: 3.318

5.  BNP predicts chemotherapy-related cardiotoxicity and death: comparison with gated equilibrium radionuclide ventriculography.

Authors:  Dorthe Skovgaard; Philip Hasbak; Andreas Kjaer
Journal:  PLoS One       Date:  2014-05-06       Impact factor: 3.240

6.  Cardiotoxicity of anthracycline therapy: current perspectives.

Authors:  Mihaela Valcovici; Florina Andrica; Corina Serban; Simona Dragan
Journal:  Arch Med Sci       Date:  2016-04-12       Impact factor: 3.318

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.